Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Wesfarmers (ASX:WES) share price rises after $135 million InstantScripts deal

The Wesfarmers Ltd (ASX:WES) share price is up around 0.5% after the company announced a deal to buy InstantScripts for around $135 million. 

The Wesfarmers Ltd (ASX: WES) share price is up around 0.5% after the company announced a deal to buy InstantScripts for around $135 million.

InstantScripts is described as one of Australia’s leading telehealth businesses.

Wesfarmers expands the healthcare division

InstantScripts is a business that helps “hundreds of thousands” of Australians access health and medical services from their home.

On the portal, Aussies can access prescriptions for everyday medications, speak to a doctor, obtain medical certificates, get blood test requests and more. It provides access for prescriptions for over 300 medications and it works with over 2,500 pharmacies across Australia.

Wesfarmers Health Managing Director, Emily Amos said that this business was complementary to the existing health portfolio, and that the acquisition would “provide opportunities to leverage its existing pharmacy and Clear Skincare networks.” Amos said:

Over recent years telehealth has emerged as an important service, complementing the care delivered through GP practices, pharmacies and other allied health providers.

Our goal is to make Australians’ health, beauty and wellness experiences simpler, more affordable and easier to access. InstantScripts provides flexible services that are available at short notice and outside of normal consultation hours, and is accessible to patients in remote areas and those who have difficulty visiting a GP.

Wesfarmers Health plans to invest in the continuing growth of InstantScripts and the expansion of digital health services for patients.

The InstantScripts clinical governance framework is well structured and we welcome the opportunity to apply Wesfarmers Health’s expertise and relationships to further strengthen and improve clinical outcomes for our patients.

Final thoughts on the Wesfarmers share price

The company’s healthcare division is still small compared to other segments of the company, like Bunnings and Kmart. I like the direction the company is taking, with a long-term outlook focus. While this won’t move the needle much for the company, I believe it’s a good move by the business.

When we combine this with other moves such as the expansion into lithium with Mt Holland, and Bunnings’ ongoing success, Wesfarmers is a great business that I’d want to own in my portfolio.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content